Rheonix Scientist Addresses Challenges of Microfluidic IVD Product Commercialization

ITHACA, N.Y. – The discovery and development of microfluidic sensors hold great promise for the design of revolutionary diagnostic devices capable of complex analysis, in a disposable format, with minimal user intervention. However, many devices in this category have faced challenges to their widespread adoption.

Rheonix Inc., an Ithaca-based developer of an automated molecular testing platform, has successfully navigated the technological hurdles and solved many of the challenges in this area. At the 2nd International Conference and Exhibition on Biosensors & Bioelectronics in Northbrook, Ill., next week, Peng Li, Ph.D., application scientist at Rheonix, will present a summary of the commercialization process of the Chemistry and Reagent Device (CARD®) cartridge technology developed by Rheonix. The CARD is a microfluidic platform that enables automation of a wide range of in vitro diagnostics applications with various work flows on a single plastic disposable cartridge. The CARD is not yet approved by the Food and Drug Administration for clinical diagnostic use.

“There are many obstacles to overcome in developing a successful commercial microfluidic device. The key to success of our technology lies in its ability to handle raw clinical samples in ranges from microliter volumes to samples in excess of 1 mL, and excellent manufacturability for mass production,” Li said. ”The interface between the macroscopic world and the microfluidic device itself (i.e., ‘world-to-chip’ interface) also accounts for some of the commercial challenges that others in this field have faced in their device development, and the Rheonix CARD has successfully navigated these issues.”

The conference is hosted by OMICS Group, an open access publication model that enables the dissemination of research articles to the global community, and brings together students, postdocs and established scientists to exchange their ideas and contributions to an integrative approach to biosensors and bioelectronics research.

Li works closely with biologists and engineers to develop sample-in result-out microfluidics-based molecular diagnostic devices. He has authored and co-authored 17 papers in peer-reviewed journals and conference proceedings and is an editor or invited reviewer for several reputed journals. He holds two U.S. patents or provisional patents in the area of microfluidics.

“We are fortunate to have scientists of Li’s caliber working toward diagnostic solutions to the problems that hospitals, laboratories and physicians face in obtaining access to the advanced molecular diagnostic tools that can help treat patients with serious and even life-threatening illnesses,” said Tony Eisenhut, Rheonix president.

The 2nd International Conference and Exhibition on Biosensors & Bioelectronics is June 17-19 at the Hilton Chicago. Li’s talk, “The Challenges of Developing and Commercializing Microfluidic Devices for In Vitro Diagnostics Applications,” is scheduled for 3:20 p.m. on June 17.